AstraZeneca PLC (AZN)vsPennant Group Inc (PNTG)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
PNTG
Pennant Group Inc
$39.20
-0.25%
HEALTHCARE · Cap: $1.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 5470% more annual revenue ($61.37B vs $1.10B). AZN leads profitability with a 17.0% profit margin vs 2.9%. AZN appears more attractively valued with a PEG of 1.28. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PNTG
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for PNTG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 35.8% year-over-year
Earnings expanding 25.0% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Distress zone — elevated risk
Smaller company, higher risk/reward
2.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PNTG
The strongest argument for PNTG centers on Revenue Growth, EPS Growth. Revenue growth of 35.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PNTG
The primary concerns for PNTG are PEG Ratio, Altman Z-Score, Market Cap. A P/E of 42.2x leaves little room for execution misses. Thin 2.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while PNTG is a hypergrowth play — different risk/reward profiles.
PNTG carries more volatility with a beta of 1.27 — expect wider price swings.
PNTG is growing revenue faster at 35.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 59/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Pennant Group Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Pennant Group, Inc. provides health care services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company is headquartered in Eagle, Idaho.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?